[Abstract] Glioma stem cells (GSC) grown as neurospheres exhibit similar characteristics to neural stem cells (NSC) grown as neurospheres, including the ability to self-renew and differentiate. GSCs are thought to play a role in cancer initiation and progression. Self-renewal potential of GSCs is thought to reflect many characteristics associated with malignancy, including tumor recurrence following cytotoxic therapy due to their proliferative dormancy and capacity to allow for the development of resistant tumor cell sub-clones due to mutations acquired during their differentiation. Here, we demonstrate that using extreme limiting dilution analysis (ELDA), subtle differences in the frequency of sphere-forming potential between PI3K-mutant oncogenic NSCs and non-oncogenic NSCs can be measured, in vitro. We further show how ELDA can be used on cells, before and after forced differentiation to amplify inherent differences in sphere-forming potential between mutant and control NSCs. Ultimately, ELDA exploits a difference in the ability of a single or a few seeded stem cells to self-renew, divide and form neurospheres. Importantly, the assay also allows a comparison between genetically distinct cells or between the same cells under different conditions, where the impact of target-specific drugs or other novel cancer stem cell therapies can be tested.
1. Pipette tips: 10 ml, 5 ml, 2 ml (Axygen) 
C. Neural stem cell differentiation
This protocol is used to culture NSC cells in differentiation media for 7 days, harvest cells, then culture back in neurosphere medium (see Figure 2F ).
Resuspend NSC single cell suspension in differentiation medium (DMEM-F12, 10% Fetal Calf
Serum, penicillin-streptomycin [100 U/ml]).
2. Seed 1 x 10 5 cells/well onto a 6-well standard adherent cell culture treated plate, pre-coated with laminin.
3. Add 2 ml of differentiated medium to each well.
4. Incubate in a 37 °C, 5% CO2 humidified incubator for 7 days to allow differentiation.
5. Replenish medium every second day. Penicillin-streptomycin (100 U/ml) 1x B27 (from 50x stock) 10 ng/ml EGF 10 ng/ml bFGF 3. Differentiated media
DMEM/F12
Penicillin-streptomycin (100 U/ml)
10% FCS
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